Moderna and Merck Revive mRNA Hopes With Melanoma Success

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss. (Source: Bloomberg)

Read it at Bloomberg Technology ↗

← Front page